Blog
RSS FeedPosted by Michael Wonder on 19 Jul 2021
Lilly and Incyte provide update on supplemental new drug application for baricitinib for the treatment of moderate to severe atopic dermatitis
16 July 2021 - Eli Lilly and Incyte announced today that the U.S. FDA will not meet the Prescription Drug User ...
Posted by Michael Wonder on 19 Jul 2021
AbbVie provides update regarding Rinvoq (upadacitinib) for the treatment of moderate to severe atopic dermatitis in the U.S.
16 July 2021 - AbbVie today announced the U.S. FDA did not meet the Prescription Drug User Fee Act action ...
Posted by Michael Wonder on 19 Jul 2021
Decision to fund rasagiline
16 July 2021 - PHARMAC is pleased to announce the decision to fund rasagiline (Azilect) a new treatment for people ...
Posted by Michael Wonder on 18 Jul 2021
Considering and communicating uncertainty in health technology assessment
15 July 2021 - As health technology assessment seeks to combine complex sets of evidence, values, and perspectives to support open, ...
Posted by Michael Wonder on 10 Jul 2021
FDA seeks to probe talks between staff and Biogen on Alzheimer’s drug
9 July 2021 - The FDA’s chief is taking the highly unusual step of asking for a federal investigation of doctors ...
Posted by Michael Wonder on 01 Jul 2021
PHARMAC is seeking views on declining funding applications
29 June 2021 - PHARMAC is considering declining 97 inactive medicine funding applications. ...
Posted by Michael Wonder on 24 Jun 2021
Moving patient stories highlight opportunities to strengthen our health care systems for all Australians
24 June 2021 - It was an emotional evening among the nearly 200 in-person and online attendees at Parliament House last ...
Posted by Michael Wonder on 17 Jun 2021
Shared decision making underpins good health care
17 June 2021 - Shared decision making between service users and health care professionals is an integral part of health care, ...
Posted by Michael Wonder on 15 Jun 2021
Health care funding decisions and real world benefits: reducing bias by matching untreated patients
14 June 2021 - Governments and health insurers often make funding decisions based on health gains from randomised controlled trials. ...
Posted by Michael Wonder on 15 Jun 2021
How the patient voice is becoming vital for drug approval
14 June 2021 - Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a ...
Posted by Michael Wonder on 09 Jun 2021
Stop blaming PHARMAC - we'd be worse off without it
10 June 2021 - Penny Tucker is concerned that there are “miracle drugs and biologics that have transformed many conditions ...
Posted by Michael Wonder on 09 Jun 2021
AMA and Australian Government agree to strengthening the MBS review process and informed financial consent
8 June 2021 - The Australian Government and the Australian Medical Association have reached agreement to work together to co-design the ...
Posted by Michael Wonder on 27 May 2021
'Anticancer drug should extend life for 22 months to get insurance benefits'
27 May 2021 - A research team at National Cancer Center has found that the public believes that for an ...
Posted by Michael Wonder on 21 May 2021
PHARMAC to work with others to improve communication
21 May 2021 - PHARMAC accepts the Coroner’s comments that not all information about the brand change reached patients. ...
Posted by Michael Wonder on 17 May 2021
Quality, access, and the use of real world data by payers: where are we now? Where do we want to be in the future?
15 May 2021 - One of the biggest challenges payers face today is determining the value of innovative therapies in diseases ...